Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Therapeutic Targeting of Syk in Autoimmune Diabetes
Lucrezia Colonna, Geoffrey Catalano, Claude Chew, et al.
The Journal of Immunology (2010) Vol. 185, Iss. 3, pp. 1532-1543
Open Access | Times Cited: 68

Showing 1-25 of 68 citing articles:

B Cells Regulate Macrophage Phenotype and Response to Chemotherapy in Squamous Carcinomas
Nesrine I. Affara, Brian Ruffell, Terry R. Medler, et al.
Cancer Cell (2014) Vol. 25, Iss. 6, pp. 809-821
Open Access | Times Cited: 279
Src-family and Syk Kinases in Activating and Inhibitory Pathways in Innate Immune Cells: Signaling Cross Talk
Clifford A. Lowell
Cold Spring Harbor Perspectives in Biology (2010) Vol. 3, Iss. 3, pp. a002352-a002352
Open Access | Times Cited: 250
Exploring Diseases/Traits and Blood Proteins Causally Related to Expression of ACE2, the Putative Receptor of SARS-CoV-2: A Mendelian Randomization Analysis Highlights Tentative Relevance of Diabetes-Related Traits
Shitao Rao, Alexandria Lau, Hon‐Cheong So
Diabetes Care (2020) Vol. 43, Iss. 7, pp. 1416-1426
Open Access | Times Cited: 237
Getting Syk: spleen tyrosine kinase as a therapeutic target
Robert L. Geahlen
Trends in Pharmacological Sciences (2014) Vol. 35, Iss. 8, pp. 414-422
Open Access | Times Cited: 213
Immune-inflammation gene signatures in endometriosis patients
Soo Hyun Ahn, Kasra Khalaj, Steven L. Young, et al.
Fertility and Sterility (2016) Vol. 106, Iss. 6, pp. 1420-1431.e7
Open Access | Times Cited: 158
Discovery of GS-9973, a Selective and Orally Efficacious Inhibitor of Spleen Tyrosine Kinase
Kevin Currie, Jeffrey E. Kropf, Tony Lee, et al.
Journal of Medicinal Chemistry (2014) Vol. 57, Iss. 9, pp. 3856-3873
Closed Access | Times Cited: 153
Recent advances in understanding spleen tyrosine kinase (SYK) in human biology and disease, with a focus on fostamatinib
Nichola Cooper, Waleed Ghanima, Quentin A. Hill, et al.
Platelets (2022) Vol. 34, Iss. 1
Open Access | Times Cited: 53
Discovery and Development of Spleen Tyrosine Kinase (SYK) Inhibitors
Rajinder Singh, Esteban S. Masuda, Donald G. Payan
Journal of Medicinal Chemistry (2012) Vol. 55, Iss. 8, pp. 3614-3643
Closed Access | Times Cited: 95
Deletion of Syk in Neutrophils Prevents Immune Complex Arthritis
Emily Elliott, Jessica A. Van Ziffle, Patrizia Scapini, et al.
The Journal of Immunology (2011) Vol. 187, Iss. 8, pp. 4319-4330
Open Access | Times Cited: 89
The Novel Kinase Inhibitor PRT062070 (Cerdulatinib) Demonstrates Efficacy in Models of Autoimmunity and B-Cell Cancer
Greg Coffey, Andreas Betz, Francis DeGuzman, et al.
Journal of Pharmacology and Experimental Therapeutics (2014) Vol. 351, Iss. 3, pp. 538-548
Closed Access | Times Cited: 83
Fostamatinib for Persistent/Chronic Adult Immune Thrombocytopenia
Adrian C. Newland, Eun‐Ju Lee, Vickie McDonald, et al.
Immunotherapy (2017) Vol. 10, Iss. 1, pp. 9-25
Open Access | Times Cited: 65
Targeting Bruton’s Tyrosine Kinase in Inflammatory and Autoimmune Pathologies
Stefan F. H. Neys, Rudi W. Hendriks, Odilia B. J. Corneth
Frontiers in Cell and Developmental Biology (2021) Vol. 9
Open Access | Times Cited: 42
A genomics perspective of personalized prevention and management of obesity
Kalliopi Gkouskou, Maria G. Grammatikopoulou, Evgenia Lazou, et al.
Human Genomics (2024) Vol. 18, Iss. 1
Open Access | Times Cited: 7
B-cell selection and the development of autoantibodies
Natalia V. Giltiay, Craig P. Chappell, Edward A. Clark
Arthritis Research & Therapy (2012) Vol. 14, Iss. Suppl 4, pp. S1-S1
Open Access | Times Cited: 71
B-Cell Receptor Signaling Inhibitors for Treatment of Autoimmune Inflammatory Diseases and B-Cell Malignancies
Kamal D. Puri, Julie A. Di Paolo, Michael R. Gold
International Reviews of Immunology (2013) Vol. 32, Iss. 4, pp. 397-427
Closed Access | Times Cited: 64
Evaluation of the Therapeutic Potential of Bone Marrow-Derived Myeloid Suppressor Cell (MDSC) Adoptive Transfer in Mouse Models of Autoimmunity and Allograft Rejection
Lucile Drujont, Laura Carretero-Iglesia, Laurence Bouchet‐Delbos, et al.
PLoS ONE (2014) Vol. 9, Iss. 6, pp. e100013-e100013
Open Access | Times Cited: 61
Involvement of B Cells, Immunoglobulins, and Syk in the Pathogenesis of Abdominal Aortic Aneurysm
Aya Furusho, Hiroki Aoki, Satoko Ohno‐Urabe, et al.
Journal of the American Heart Association (2018) Vol. 7, Iss. 6
Open Access | Times Cited: 55
Spleen Tyrosine Kinase Inhibition Attenuates Autoantibody Production and Reverses Experimental Autoimmune GN
Stephen P. McAdoo, John J. Reynolds, Gurjeet Bhangal, et al.
Journal of the American Society of Nephrology (2014) Vol. 25, Iss. 10, pp. 2291-2302
Open Access | Times Cited: 52
The Oral Spleen Tyrosine Kinase Inhibitor Fostamatinib Attenuates Inflammation and Atherogenesis in Low-Density Lipoprotein Receptor–Deficient Mice
Ingo Hilgendorf, S. Eisele, Imke Remer, et al.
Arteriosclerosis Thrombosis and Vascular Biology (2011) Vol. 31, Iss. 9, pp. 1991-1999
Closed Access | Times Cited: 57
Imidazotriazines: Spleen Tyrosine Kinase (Syk) Inhibitors Identified by Free‐Energy Perturbation (FEP)
Frank Lovering, Cristina Aevazelis, Jeanne S. Chang, et al.
ChemMedChem (2015) Vol. 11, Iss. 2, pp. 217-233
Closed Access | Times Cited: 46
OSKIRA-4: a phase IIb randomised, placebo-controlled study of the efficacy and safety of fostamatinib monotherapy
Peter C. Taylor, Mark C. Genovese, Mike Greenwood, et al.
Annals of the Rheumatic Diseases (2014) Vol. 74, Iss. 12, pp. 2123-2129
Closed Access | Times Cited: 42
Application and prospect of targeting innate immune sensors in the treatment of autoimmune diseases
Jun Liu, Hui Zhang, Yanhong Su, et al.
Cell & Bioscience (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 21
Long-term safety and efficacy of fostamatinib in Japanese patients with primary immune thrombocytopenia
Masataka Kuwana, Yoshiaki Tomiyama
International Journal of Hematology (2025)
Open Access
Spleen Tyrosine Kinase: A Crucial Player and Potential Therapeutic Target in Renal Disease
Terry King‐Wing, Stephen P. McAdoo, Frederick Wai-Keung Tam
˜The œNephron journals/Nephron journals (2016) Vol. 133, Iss. 4, pp. 261-269
Open Access | Times Cited: 32
Fostamatinib disodium
Stephen P. McAdoo, Frederick W.K. Tam
Drugs of the Future (2011) Vol. 36, Iss. 4, pp. 273-273
Open Access | Times Cited: 38
Page 1 - Next Page

Scroll to top